Physician profile
Abdul Hafeez
NPI 1023082005
$3,504.77
in general payments reported to CMS, 2019-2025
24 companies · $560 in 2025
The $560 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $148 · 2021: $237 · 2022: $597 · 2023: $888 · 2024: $850 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,994 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.63 |
| Education | $304.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.42 | 2019-2024 | |
| Janssen Biotech, INC. | $530.60 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $511.73 | 2022-2025 | Sotyktu |
| Pfizer INC. | $333.87 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $291.76 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $146.79 | 2019-2024 | |
| Boston Scientific Corporation | $142.93 | 2023 | Watchman Access System |
| Amgen INC. | $133.74 | 2022-2025 | Otezla |
| Incyte Corporation | $132.90 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $90.39 | 2021-2022 | |
| Ucb, INC. | $87.11 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $85.20 | 2019-2025 | |
| Journey Medical Corporation | $57.58 | 2020-2021 | |
| Dermavant Sciences, INC. | $56.99 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $52.68 | 2020-2025 | Nemluvio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $49.86 | 2022-2025 | Uzedy |
| Lilly USA, LLC | $48.96 | 2024 | Olumiant, Taltz |
| Leo Pharma INC. | $41.44 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $29.68 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $26.29 | 2025 | |
| Organon LLC | $25.74 | 2025 | Vtama |
| Genzyme Corporation | $24.77 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.41 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.93 | 2025 | Cabtreo, Siliq, Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Hafeez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.